when is semaglutide off patent With semaglutide's expiring, generics are set to enter from soon, setting competition in a fast-growing segment of obesity and diabetes care. https://timesofindia.indiatimes.com/toi-plus/business-economy/why-miracle-weight-loss-drugs-are Looming GLP-1 drug patent expirations

As of 2024, retatrutide has not received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) and remains an experimental compound

By regulating appetite and metabolism, GLP-1 injections assist in creating a caloric deficit, which is essential for weight loss

The majority of gastrointestinal events were classified as mild to moderate in severity, and most resolved without requiring permanent discontinuation of the drug

TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes with continued loss to 30.3% at 104 weeks in the extension cohort